These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 32319309)

  • 1. ARNI in cardiovascular disease: current evidence and future perspectives.
    Kuchulakanti PK
    Future Cardiol; 2020 Sep; 16(5):505-515. PubMed ID: 32319309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction.
    Docherty KF; McMurray JJV
    Int J Cardiol; 2019 Apr; 281():179-185. PubMed ID: 29891240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
    Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV
    JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond.
    Kario K
    Curr Cardiol Rep; 2018 Jan; 20(1):5. PubMed ID: 29374807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neprilysin Inhibitors in Heart Failure: The Science, Mechanism of Action, Clinical Studies, and Unanswered Questions.
    Bozkurt B; Nair AP; Misra A; Scott CZ; Mahar JH; Fedson S
    JACC Basic Transl Sci; 2023 Jan; 8(1):88-105. PubMed ID: 36777165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective.
    Chin KL; Zomer E; Wang BH; Liew D
    Heart Lung Circ; 2020 Sep; 29(9):1310-1317. PubMed ID: 32303468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sacubitril/Valsartan (LCZ696) in Heart Failure.
    Khder Y; Shi V; McMurray JJV; Lefkowitz MP
    Handb Exp Pharmacol; 2017; 243():133-165. PubMed ID: 28004291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination Therapy of Renin Angiotensin System Inhibitors and β-Blockers in Patients with Heart Failure.
    Nochioka K; Sakata Y; Shimokawa H
    Adv Exp Med Biol; 2018; 1067():17-30. PubMed ID: 29542073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
    Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF.
    Balmforth C; Simpson J; Shen L; Jhund PS; Lefkowitz M; Rizkala AR; Rouleau JL; Shi V; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
    JACC Heart Fail; 2019 Jun; 7(6):457-465. PubMed ID: 31078482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin-Neprilysin Inhibition as a Paradigm for All?
    Vaduganathan M; Desai AS
    Curr Cardiol Rep; 2016 Nov; 18(11):115. PubMed ID: 27747488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction.
    Cannon JA; Shen L; Jhund PS; Kristensen SL; Køber L; Chen F; Gong J; Lefkowitz MP; Rouleau JL; Shi VC; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJ;
    Eur J Heart Fail; 2017 Jan; 19(1):129-137. PubMed ID: 27868321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities.
    Albert NM; Tyson RJ; Hill CL; DeVore AD; Spertus JA; Duffy C; Butler J; Patterson JH; Hernandez AF; Williams FB; Thomas L; Fonarow GC
    Am Heart J; 2021 May; 235():82-96. PubMed ID: 33497697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.
    King JB; Shah RU; Bress AP; Nelson RE; Bellows BK
    JACC Heart Fail; 2016 May; 4(5):392-402. PubMed ID: 27039128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [ANMCO position paper on sacubitril/valsartan in the management of patients with heart failure].
    Di Tano G; Di Lenarda A; Gabrielli D; Aspromonte N; De Maria R; Frigerio M; Iacoviello M; Mortara A; Murrone A; Nardi F; Oliva F; Pontremoli R; Scherillo M; Senni M; Urbinati S; Gulizia MM
    G Ital Cardiol (Rome); 2018 Oct; 19(10):568-590. PubMed ID: 30281045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-Analysis Evaluating the Effects of Renin-Angiotensin-Aldosterone System Blockade on Outcomes of Heart Failure With Preserved Ejection Fraction.
    Kuno T; Ueyama H; Fujisaki T; Briasouli A; Takagi H; Briasoulis A
    Am J Cardiol; 2020 Apr; 125(8):1187-1193. PubMed ID: 32081366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction.
    Khariton Y; Fonarow GC; Arnold SV; Hellkamp A; Nassif ME; Sharma PP; Butler J; Thomas L; Duffy CI; DeVore AD; Albert NM; Patterson JH; Williams FB; McCague K; Spertus JA
    JACC Heart Fail; 2019 Nov; 7(11):933-941. PubMed ID: 31521679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.